A sthma affects 1 100 000 children in the UK and is thus the most common long-term condition of childhood. The prevalence of childhood asthma symptoms in the UK is among the highest worldwide and this contributes to the estimated £1 billion annual cost of asthma care to the NHS. Children still die from asthma despite advances in its management, and mortality rates have changed very little over the past 20 years. The recent national review of asthma deaths provided a stark reminder of 'why asthma still kills' and made key recommendations for children with asthma. However, evidence-based recommendations are still poorly implemented. This article seeks to enthuse the next generation of GPs to prioritise the improvement of asthma care in children.
summarises the diagnostic process recommended by the British Thoracic Society (BTS) and Scottish Intercollegiate Guidelines Network (SIGN). There is no definitive gold standard test that can categorically confirm the diagnosis of asthma. Instead, asthma is diagnosed based on evidence collected from a structured clinical assessment, together with (ideally) confirmation of variable airflow obstruction, e.g. by spirometry or serial peak expiratory flow readings (BTS/SIGN, 2016) . History Suspect asthma in any child experiencing more than one of the following symptoms: . Wheeze . Breathlessness . Cough . Episodic chest tightness Recurrent episodes may be triggered by exposure to allergens, viral infection, or exacerbated by exercise, cold air, emotion or laughter. Diurnal variation of symptoms is common, with symptoms being worse at night or in the early morning. Remember to ask about existing atopic conditions, such as eczema or allergic rhinitis and a family history of atopy or asthma: if present, the likelihood of asthma is higher.
Examination
Respiratory examination may well be normal if the child is asymptomatic, so it is important not to exclude asthma solely on examination findings. Examination should not just include the respiratory system. Examine the throat for enlarged tonsils, as these may be associated with obstructive sleep apnoea (snoring and noisy breathing at night), or co-exist with adenoidal enlargement (promote mouth-breathing and contribute to a dry, irritant cough during sleep). Examine the skin and nose for signs of atopy. Wheeze in asthma tends to be scattered, polyphonic and end-inspiratory. If wheeze is never heard during symptomatic episodes, alternative diagnoses should be considered. Consider the symptoms and signs that suggest diagnoses other than asthma (Table 1 ).
Further investigation
It is important to recognise that a structured clinical assessment should incorporate all available evidence. The history and examination are key components, but information from the child's record could help in the diagnosis of asthma. For example, a past entry of wheeze heard on chest auscultation recorded by a doctor or nurse; a previous blood test showing eosinophilia; past skin prick test results showing positivity for aeroallergens (BTS/SIGN, 2016) .
Currently not widely available in UK general practice, fractional exhaled nitric oxide (FeNO), is quick and can be performed by children aged 5 or older. A positive FeNO test can demonstrate airways inflammation and increases the probability of asthma; however, a negative test does not exclude asthma (BTS/SIGN, 2016) .
With the initial assessment complete, decide how to proceed based on the probability that the child has asthma. The pathways are outlined in Table 2 .
Chest X-ray
A chest X-ray is not necessary in the diagnostic work-up of a child with suspected asthma. However, it may be considered for cases where an alternative condition is suspected or in severe disease (BTS/SIGN, 2016).
Avoiding over-diagnosis
Wrongly labelling children with a diagnosis of asthma can lead to unnecessary treatment and anxiety (Looijmans-van den Akker, van Luijn, & Verheij, 2016) . The variable nature of asthma can mean that individuals may experience long periods without symptoms, and it is not infrequent that asthma in children remits (Strachan, Butland, & Anderson, 1996) . To discern between over-diagnosis and 'inactive' asthma, it is essential to record the basis on which a diagnosis was made, so that, if questioned later, it can be reviewed (BTS/SIGN, 2016) . A prescription of asthma treatment should always be accompanied by on-going review and reassessment, with a view to reducing or ultimately stopping medication if a child remains symptom-free.
If a child is commenced on a trial of treatment (usually inhaled corticosteroids), it should be for a maximum of 6 weeks, and stopped at the end of the trial, regardless of the clinical picture (Bush & Fleming, 2016) . If the child has had no response to treatment (ideally based on objective results), the diagnosis of asthma is unlikely. If, however, symptoms improve with inhaled corticosteroids, but recur when stopped, and then settle again with reintroduction of treatment, a diagnosis of asthma can be made. If a trial of treatment is started it is important to ensure that the dosage is correct, and that the treatment is given correctly. This can be achieved by early referral to the practice or respiratory nurse for education on inhaler technique and other aspects of selfmanagement. 
Intermittent reliever therapy
Short-acting b 2 agonists (salbutamol) should be prescribed as a short-term reliever of symptoms. In a minority of children with mild intermittent asthma or mild exercise-induced asthma, it may be possible to treat with occasional reliever therapy only (BTS/SIGN, 2016).
Children with good asthma control should need little or no short-acting b 2 agonists. If children are being issued with regular repeat prescriptions for salbutamol inhalers, then this raises questions about their asthma management. Is their asthma poorly controlled? Are they using their inhaler(s) correctly? Overuse of short-acting b 2 agonists and underuse of inhaled corticosteroids is common, and was highlighted as a key action point by the national review of asthma deaths (Levy et al., 2014) . Children requesting more than one short-acting b 2 agonists a month should be contacted to clarify their usage and have their asthma assessed (BTS/SIGN, 2016).
Suspected asthma: Monitored initiation of treatment
Following diagnosis of asthma or as a trial of treatment with a suspicion of asthma, a very-low-to-low dose inhaled steroid should be commenced (Fig. 2 ). To bring clarity to the comparative strengths of different inhalers, the BTS/SIGN (2016) update has listed doses of inhaled corticosteroids as very low (usually paediatric doses), low, medium and high. Clenil Modulite can be prescribed by trade name, as it is currently the only pressurised metered dose inhaler (pMDI) CFC-free product with a paediatric licence. A dose of 100 micrograms twice daily would be a recommended starting point, with follow-up arranged at 6 weeks.
Regular preventer
If the initiation period is successful, treatment should be continued as regular preventer therapy. The dose of inhaled corticosteroids can be optimised over time up to a maximum of 200 microgram twice daily. Remember that long-term inhaled corticosteroid of 400 microgram (budesonide diproprionate and equivalent) or more a day may lead to systemic side-effects, such as growth failure and adrenal suppression (BTS/SIGN, 2016); children on these doses long term should be reviewed by a hospital specialist. At each increase of dose, children should be reviewed and the response to treatment assessed, with height and weight monitored annually. Ultimately, the aim is to achieve disease control at the lowest possible dose of inhaled corticosteroid. 
Level of probability Diagnosis
High probability Asthma diagnosis is likely, complete a trial of treatment.
Low probability An alternative diagnosis is likely, consider further investigation and referral as clinically indicated
Intermediate probability Diagnosis is uncertain. Additional steps are needed to further evaluate the likelihood of asthma:
. A trial of treatment can be considered, reviewing after a defined period . If a child is able, seek confirmation of variable airflow obstruction, which can be achieved by spirometry or (conveniently in primary care) comparing peak expiratory flow when symptomatic with readings taken when the child is well. To gain accurate spirometry readings in children the operator should have paediatricspecific training -even then there is a substantial false positive rate . If uncertainty remains despite the further steps taken, refer for a specialist opinion 
Initial add-on preventer
Long-acting bronchodilators are licensed for use as add-on therapy in children aged 5 years and above. Evidence presented in Weatherall, Wijesinghe, Perrin, Harwood, and Beasley (2010) cautions against the use of longacting beta agonist (i.e. salmeterol) as a monotherapy, due to the increased risk of asthma mortality. Accordingly, and particularly as adherence with any long-term condition is a challenge, all long-acting bronchodilators should be prescribed as a combination therapy.
Montelukast is an alternative add-on therapy for those aged over 5 years, or can be considered for use as a monotherapy in those aged less than 5 years (BTS/ SIGN, 2016). As an oral preparation, it is generally well-tolerated with relatively few side-effects and is given at bedtime. Montelukast should be discontinued if there is no perceived clinical benefit after a trial period of 3 months.
Children can often have seasonal asthma dependent on trigger factors, so it may be feasible to reduce and even discontinue therapies out of season. With any stepdown in therapy, parents should be given clear self-management advice on home asthma monitoring and when to increase treatment and seek medical review.
High-dose therapies
A proportion of children will continue to experience symptoms despite add-on therapies. Prior to referral to secondary care (Box 1), assess adherence to treatment by reviewing repeat prescriptions, inhaler technique and the child's asthma action plan to ensure that the family fully understands the plan and when to take the medication. Ensure that any under-treated rhinitis is managed with nasal steroids and antihistamines (Scadding et al., 2007) . Other existing co-morbidities and tobacco smoke in the household may also limit response to treatment. . If doubt about diagnosis remains, including failure to respond to a trial of treatment . Failure to respond to treatment despite trial of add-on preventer therapies . Rapid escalation through therapies . Long-term high-dose (400 micrograms daily) inhaled corticosteroids . Frequent exacerbations requiring oral steroids . Co-existing food allergy, especially to peanuts or tree nuts . Parental concern or anxiety . Supported self-management is a key component of asthma care, it should be provided routinely for every child with asthma. Asthma self-management should include education about self-monitoring of symptoms (or peak expiratory flow), along with a regular medical review and a personal asthma action plan (Gibson et al., 2002) . Education should be patient-centred and tailored to the child and parent's understanding, encompassing topics such as: recognising and responding to worsening asthma control, identifying and avoiding individual triggers, peak expiratory flow monitoring (if preferred) and inhaler use. Keep in mind the dangers of smoking around a child with asthma and, if appropriate, offer smoking cessation support to parents.
An annual review by a doctor or nurse will provide an opportunity to confirm the diagnosis, the treatment and self-management plan. Reviews may be more frequent, based on individual patient needs. Any asthma attack that leads to an emergency visit to hospital is an indicator of risk in the future; the child should be reviewed in primary care within 2 days (Bush and Fleming, 2015) .
Supported self-management is effective. There are benefits for the child, including better asthma control, reduced absence at school, reduced emergency department visits, hospital admissions and unscheduled appointments (Boyd et al., 2009; Gibson et al., 2002) .
Completing a personal asthma action plan
Personal asthma action plans (Fig. 3) are an important aspect of self-management and have been validated for children aged 5 years or older (Boyd et al., 2009 ). Despite the known benefits, less than a third of asthma patients have one (Asthma UK, 2014 ). An asthma action plan provides written guidance of current treatment, triggers to avoid, and steps to take if asthma control deteriorates. Completing an action plan together with a parent and child provides a good structure for discussing management, so it is important to be familiar with the content, and know how to access one easily, either through an asthma template on general practice software or directly from a website such as Asthma UK (asthma.org.uk).
Monitoring asthma control can be based on parent and child recognising worsening symptoms, or in older children, a drop in peak expiratory flow. If peak expiratory flow is used, the percentage of personal best (not predicted) is best practice (Gibson & Powell, 2004) . Widely accepted thresholds for treatment are a fall in peak flow to 80% of personal best for starting regular reliever medication for a defined period (BTS/SIGN, 2016): four puffs four times a day for 4 days is a useful guide. The recommendation to seek urgent clinical advice is based on the ............................................................................................................................................................................................................................ severity of symptoms and a fall in peak expiratory flow below 50% of personal best. BTS/SIGN (2016) provides clear age-appropriate guidance for the assessment and management of children presenting with an asthma attack (Fig. 4) . To build on the guideline, the following section considers practical points and common pitfalls.
Oxygen saturation monitoring: Professionals and parents
Having access to a pulse oximeter is essential in the assessment of children with acute wheeze. However, care should be taken when using equipment not intended for paediatric use, as it can produce incorrect readings.
Pulse oximeters are readily available for parents to purchase, and may be used at home to make assessments regarding their own child. Although there is no evidence to support or refute the use of saturation monitors as part of a personalised asthma action plan, using a monitor without the knowledge and skills to interpret and act upon results leads to risks. In particular, the importance of interpreting results in the context of the whole clinical picture and not in isolation should be stressed (Welsh and Carr, 2013) .
Children under 2 years in age
Children under the age of 2 years and who present with an acute wheeze are most likely to have bronchiolitis, in which case, prednisolone is unlikely to provide any clinical benefit (Fernandes et al., 2013) . Each child, however, should be assessed individually, as the child may have multi-trigger wheeze or a personal or family history of atopy that may increase the probability of an asthma diagnosis. If steroids are prescribed, it is important to document clinical response and time to resolution of symptoms.
Children over 2 years in age
Acute wheeze has been treated with 'multi-dose' salbutamol in the majority of secondary care settings since the early-2000s, and this has increasingly become the norm in primary care. The benefits when compared with nebulised beta-agonist include a reduced length of stay in the emergency department, a lower heart rate and fewer systemic side-effects (Cates, Welsh, & Rowe, 2013) . Additionally, parents are able to instigate emergency treatment at home as part of their asthma action plan and reinforces to them the need to seek urgent medical review if this is ineffective. BTS/SIGN (2016) advises a dose of 200 micrograms (two puffs) to 1000 micrograms (10 puffs), depending on the severity of symptoms.
However, the majority of hospitals in the UK consider 10 puffs as the 'multi-dose'.
Nebuliser: When and how?
The use of air-driven nebulisers for the treatment of acute severe wheeze should be discouraged. Salbutamol, when given via an air-driven nebulizer, results in pulmonary vasodilation, increasing perfusion to poorly ventilated lung units, and ventilation/perfusion mismatch. Worsening hypoxaemia is the result, and this has led to the death of a child in a primary care setting (Inwald, Roland, Kuitert, McKenzie, & Petros, 2001) . Therefore, in the event of being faced with a child presenting with severe wheeze, a nebuliser should be administered via oxygen at a flow rate of 8-10 L for a maximum of 10 minutes per nebuliser. Oxygen should then continue through a non-rebreather mask.
Oral corticosteroids
Oral prednisolone should be administered to treat moderate-to-severe asthma, and should be given within an hour of presentation. A 3-day course is usually sufficient with dosing suggested at 20 mg for 2 to 5 year olds and 40 mg for children aged 5 and above. As well as tablets, prednisolone is now available as a liquid in 1 mg/1 ml and 10 mg/1 ml dilution. Providing steroids in advance for parents to instigate in the event of a deterioration in asthma control (as part of their child's self-management plan) may be considered, particularly if the family live remotely or a previous asthma attack has been severe. Safety net advice should always be given, stressing the need for medical review if steroids have been initiated at home. Essentially there are two types of devices used to treat asthma: . Aerosols, e.g. pMDI and breath-activated devices, e.g. Easibreathe . Dry powder inhaler, e.g. Easyhaler, Accuhaler pMDI or breath-activated devices contain medication that is already in an aerosol state. A slow and steady inhalation is needed. The device needs to be rested for 30 seconds between actuations to stabilise back to room temperature. Using a pMDI without a spacer is not advisable for any child, due to the difficulty with inhalation/ actuation coordination. A spacer with a mask is particularly helpful for pre-school children, however, it can be used aged 5 years and above if the child prefers or has difficulty with a mouthpiece.
Inhalers
A dry powder inhaler (DPI) contains medication in a powder form that needs to be made into an aerosol. A .................................................................................................................................................................................................................................................. fast and forceful inhalation is needed. Children should be encouraged to carry a personal device from around 8 years of age and a DPI tends to be the most cost-effective option. There are a number of devices available. Local formulary committees may recommend particular devices.
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It is important for a clinician to become familiar with at least one MDI, breath-actuated MDI and DPI, as it should be the prescriber's responsibility to teach and assess inhaler technique prior to commencing a new treatment (BTS/SIGN, 2016). Unfortunately, this does not always happen and assumptions are made that someone else (for example, the community pharmacist) will take on this role. Children and young people's inhaler technique can be influenced by their peers, family members, television and social media, and the technique learned this way may be incorrect. Inhaler technique should therefore always be assessed at the time of issue and at every asthma review. Adherence to maintenance asthma treatment is often poor. Addressing non-adherence can be made more difficult as causes are often multi-factorial and parents often over-estimate adherence. It can be helpful to think about non-adherence in two broad categories: intentional and non-intentional adherence.
Intentional non-adherence occurs when children (or their parents) decide not to take the recommended treatment after considering the risks and benefits, the impact of their symptoms or experience of side-effects (Horne, 2006) . The term non-intentional non-adherence applies when children (or their parents) simply forget to use treatment, are unable to afford treatment or misunderstand some aspect of the treatment prescribed (Nunes et al., 2009 ).
Asking about adherence in a non-judgemental style, using open questions and acknowledging that poor adherence is common, may open-up the conversation. Prescribing records can be informative; any discrepancy between treatment issued and reported can be a helpful way to broach the subject.
To address intentional non-adherence requires understanding of the child or parents' ideas and concernsare there doubts about the necessity of the prescribed treatment or concerns about potential side-effects? Some children may find taking regular preventer medication may not make appreciable difference to symptoms. Discussing these topics openly, providing education and making a shared decision are key steps in improving adherence. Practical solutions, such as an action plan to consolidate education, a change in inhaler type (dry powder rather than MDI) or switching to a once daily combination inhaler, are also useful treatment options. Asthma is common and the basic principles are wellknown to medics of all stages. However, asthma remains a disease that kills, and key evidence-based interventions are still poorly implemented. Take pride in providing high-quality asthma care, which should include a structured approach to diagnosis, prescribing responsibly with clear plans for follow-up, checking and discussing adherence to treatment and prioritising regular review as part of continuing supported self-management.
Key points
. Asthma is the most common long-term condition in childhood and remains a 'killer disease' . Recognition of asthma as a condition that varies in severity and over time is important when making a diagnosis . A trial of treatment should be for a maximum of 6 weeks, following which treatment should be stopped, regardless of the clinical picture, and the child reviewed . Address the common discovery of non-adherence to asthma treatment in a non-judgemental manner . Underuse of inhaled corticosteroids (and overuse of short-acting b 2 agonists) is common and linked to poor asthma control . Prioritise asthma self-management in consultations with children over 5 years old
